Cytotherapy

Article	Citations
An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies	168
Editorial Board	59
Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma	57
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity	49
Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease	38
Table of Contents	36
Subscription information	35
Aims and Scope	34
Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program	33
Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial	31
Targeted knockdown of MSC-sEVs biogenesis regulator proteins to elucidate the mechanisms of their production: a step towards translational applications	29
Human cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase	27
Targeted animal models for preclinical assessment of cellular and gene therapies in pancreatic and liver diseases: regulatory and practical insights	26
Table of Contents	25
Subscription information	24
Subscription information	23
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone	23
Development of T-cell immunity in a liver and hematopoietic stem cell transplant recipient following coronavirus disease 2019 infection	22
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-ba	22
Editorial Board	21
Effects of mitochondrial transplantation on chronic pressure wound healing in a human patient	21
Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy	21
Editorial Board	20
Aims and Scope	20
Aims and Scope	20

Longitudinal two-dimensional gas chromatography mass spectrometry as a non-destructive at-line monitoring tool during cell manufacturing identifies volatile features correlative to cell product qualit	20
Manufacturing and validation of Good Manufacturing Practice–compliant regulatory dendritic cells for infusion into organ transplant recipients	19
Editorial Board	19
Editorial Board	19
Aims and Scope	19
Aims and Scope	19
Early Stage Professionals Committee proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting	19
Mesenchymal Stem/Stromal Cells: EVALUATION OF SCALABLE ATTACHMENT-DEPENDENT EXPANSION SYSTEM FOR MESENCHYMAL STEM CELLS IN XENO- AND SERUM-FREE MEDIA	18
iPSC: CRYOPRESERVATION OF IPSCS IN HERMETICALLY SEALED CYCLIC OLEFIN POLYMER (COP) CONTAINER SYSTEMS	18
MITOCHONDRIAL DYSFUNCTION OF MESENCHYMAL STROMAL CELLS DERIVED FROM EMPHYSEMATOUS DONORS AND THEIR EXTRACELLULAR VESICLES CONTRIBUTES TO THE ABSENCE OF THERAPEUTIC EFFECTS IN A MURINE MODEL OF SEVERE	17
Mesenchymal Stem/Stromal Cells: TWO NEW POTENTIAL THERAPEUTIC APPROACHES IN RADIATION CYSTITIS DERIVED FROM MESENCHYMAL STEM CELLS: EXTRACELLULAR VESICLES AND CONDITIONED MEDIUM	17
Mesenchymal Stem/Stromal Cells: Late Breaking Abstract: CHARACTERISTICS OF MESENCHYMAL STEM CELLS FROM VARIOUS TISSUE SOURCE ACCORDING TO CULTURE MEDIA TYPE	17
Mesenchymal Stem/Stromal Cells: SCALE-UP OF A XENO-FREE FED-BATCH STIRRED-TANK BIOREACTOR PROCESS FOR HMSC MANUFACTURING	17
ISOLATION AND IN VITRO CHARACTERIZATION OF FELINE DENTAL PULP STEM CELLS	17
Mesenchymal Stem/Stromal Cells: REGENERATIVE MEDICINE IS GOING TO THE DOGS: TREATING CANINE EARLY ONSET PARKINSON’S DISEASE PATIENTS (EOPD OR THE PARK9 GENE) WITH ALLOGENEIC MESENCHYMAL STEM CELLS	17
THE CONNECTION BETWEEN AUTISM SPECTRUM DISORDER AND THE SCN2A AND RENL GENES	17
ONCOLYSIS MEDIATED BY INFB AND ARF GENE TRANSFER ACTIVATES KEY COMPONENTS OF THE IMMUNE SYSTEM	17
USE OF TOCILIZUMAB AND MESENCHYMAL STROMAL CELLS IN THE TREATMENT OF SEVERE COVID-19 - A CASE REPORT	16
iPSC: IDENTIFICATION AND VALIDATION OF VENTRICULAR-SPECIFIC SURFACE MARKER FOR HUMAN PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES	16
SELECTION OF GENOME EDITED HEMATOPOIETIC STEM CELLS PRIOR TO TRANSPLANTATION DECREASES THE ENGRAFTMENT POTENTIAL AND THERAPEUTIC EFFICACY	16
Mesenchymal Stem/Stromal Cells: FAR-INFRARED IRRADIATION EMITTED FROM CARBON FIBER SHEETS INCREASES OSTEOGENIC DIFFERENTIATION OF HUMAN TONSIL-DERIVED MESENCHYMAL STEM CELLS	16
iPSC: REPRODUCIBLE IPSC BIOREACTOR EXPANSION ACHIEVED THROUGH SYSTEMATIC BIOPROCESS DESIGN AND IDENTIFICATION OF KEY PROCESS INPUT VARIABLES	16
REVEALING HEART REGENERATION BY ESTABLISHMENT OF IN VIVO MODELS OF CARDIAC INJURY	16
Immunotherapy: PLATELETS INDUCE REGULATORY T-CELL EXPANSION DURING CAR-T CELL MANUFACTURING	16
Immunotherapy: AN OPTIMISED PROCESS FOR THE EXPANSION OF FUNCTIONAL CAR-TREGS FOR IMMUNOTHERAPY APPLICATIONS	16
Mesenchymal Stem/Stromal Cells: NEW ATMPS IN MEDICAL TRIALS – CASE STUDIES BY THE FAMICORD GROUP’S LEADING DEVELOPMENT PIPELINE	15
Mesenchymal Stem/Stromal Cells: A NOVEL, MULTI-SITE GMP PROTOCOL TO MANUFACTURE PROSPECTIVELY-ISOLATED, ALLOGENEIC BONE MARROW MSCS FOR A PHASE 1B CLINICAL TRIAL IN PROGRESSIVE DIABETIC KIDNEY DISEASE	15
Immunotherapy: MULTI-CENTER GAMMA-DELTA T CELL CLINICAL TRIAL PRODUCT IDENTIFICATION USING NEW PRODUCT ATTRIBUTE AND NEW CODES FOR ISBT 128 LABELING	15
BEHAVIOR OF POPULATIONS OF MESENCHYMAL STEM CELLS OBTAINED FROM THE PULP OF MOUSE INCISORS	14
Mesenchymal Stem/Stromal Cells: DURABLE RESPONSE SEEN IN PATIENTS WITH REFRACTORY FISTULIZING PERIANAL CROHN’S DISEASE USING AUTOLOGOUS MESENCHYMAL STEM CELLS ON A DISSOLVABLE MATRIX: RESULTS FROM THE	14
Mesenchymal Stem/Stromal Cells: HUMAN MSCS REDUCE INFLAMMATION AND PROMOTE REPAIR IN SEVERE HOUSE DIST MITE INDUCED ALLERGIC AIRWAY DISEASE DRIVEN BY MACROPHAGE MIGRATION INHIBITORY FACTOR	14
Mesenchymal Stem/Stromal Cells: HIGH THROUGHPUT SCREENING OF MESENCHYMAL STROMAL CELL MORPHOLOGICAL RESPONSE TO INFLAMMATORY SIGNALS FOR BIOREACTOR-BASED MANUFACTURING OF IMMUNOMODULATORY EXTRACELLULA	14
Immunotherapy: COMPARISON OF TWO HEK293 SUSPENSION CELL LINES FOR SCALABLE LENTIVIRAL VECTOR PRODUCTION	14
Mesenchymal Stem/Stromal Cells: INTERIM REPORT FROM THE NEPHSTROM MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE-1B CLINICAL TRIAL OF A NOVEL MESENCHYMAL STROMAL CELL THERAPY IN PROG	14
DEVELOPMENT OF A CRISPR-BASED ANTIVIRAL SYSTEM AGAINST BOHV-1	14
Immunotherapy: OMNI-CAR, A UNIVERSAL CAR T CELL THERAPY UTILIZING COVALENT SPYTAG/SPYCATCHER BINDING TO TARGET MULTIPLE ANTIGENS IN DIFFERENT TUMORS	14
Gene Editing/Gene Therapies: DEVELOPING A SCALABLE, CHEMICALLY-DEFINED LENTIVIRAL VECTOR PRODUCTION PROCESS FOR GENE-MODIFIED CELL THERAPIES	14
Mesenchymal Stem/Stromal Cells: DEVELOPMENT OF AN OFF-THE-SHELF ALLOGENEIC THERAPEUTIC PRODUCT INTENDED FOR BONE REGENERATION WITH IMMUNOSUPPRESSIVE PROPERTIES	14
Mesenchymal Stem/Stromal Cells: MULTIPOTENT ADULT PROGENITOR CELLS MODULATE MONOCYTE/MACROPHAGE PHENOTYPE, CYTOKINE SECRETION AND FUNCTION	13
Gene Editing/Gene Therapies: SOLUPORE® IS A NOVEL PLATFORM USED FOR THE DELIVERY OF GENE EDITING TOOLS AND MODALITIES, YIELDING HEALTHIER, EDITED PRIMARY IMMUNE CELLS WITH SUPERIOR FUNCTION COMPARED W	13
Mesenchymal Stem/Stromal Cells: ENDOTHELIAL COLONY FORMING CELL AND CD362+ MESENCHYMAL STROMAL CELL (ORBCEL-C™) COMBINATIONAL CELL THERAPY INCREASE BLOOD PERFUSION IN A MOUSE MODEL OF HINDLIMB ISCHAEM	13
Mesenchymal Stem/Stromal Cells: SAFETY OF CORD TISSUE DERIVED MESENCHYMAL STROMAL CELLS IN COVID-19 RELATED ACUTE RESPIRATORY DISTRESS SYNDROME	13
Mesenchymal Stem/Stromal Cells: IL-1β PRIMED MESENCHYMAL STROMAL CELLS PROMOTE AUTOLOGOUS SKIN ENGRAFTMENT IN AN INNOVATIVE SEVERE BURN RAT MODEL	13
Gene Editing/Gene Therapies: A GMP-COMPATIBLE PROCESS FOR THE EFFICIENT TRANSFECTION OF MSCS WITH mRNA	13
Gene Editing/Gene Therapies: HIGHLY EFFICIENT AND BIOCOMPATIBLE DELIVERY OF RNA THERAPEUTICS USING BIODRONETM PLATFORM TECHNOLOGY	13
Mesenchymal Stem/Stromal Cells: ICE RECRYSTALLIZATION INHIBITOR INCREASES POST-THAW FUNCTIONAL CAPACITY OF BONE MARROW AND UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS	13
Mesenchymal Stem/Stromal Cells: TARGETING ENDOGENOUS MESENCHYMAL STROMAL CELL RESPONSE TO INTERFERONγ IN SJÖGREN’S	13
Gene Editing/Gene Therapies: ADVANCING AAV: NOVEL SEQUENCING SOLUTIONS FOR QUALITY CONTROL IN GENE THERAPY	13
Recellularization potential of whole rat acellular kidney scaffolds utilizing the wharton’s jelly mesenchymal stromal cells: results from a preliminary study	12
IBRUTINIB INDUCES ICAM-1 EXPRESSION ON MESENCHYMAL STEM CELLS AND ENHANCES THEIR POTENTIAL TO CONTROL T-CELL RESPONSE	12

EVALUATION OF ANTI-CD19 CAR-T CELL PERSISTENCE AND EFFICACY USING A DEVELOPED MULTIPARAMETRIC FLOW CYTOMETRY AND QPCR TRACKING PLATFORM FOR PRECLINICAL AND CLINICAL STUDIES	12
Immunotherapy: EXAMINATION OF ORTHOGONAL METHODS FOR THE DETERMINATION OF VECTOR COPY NUMBER	12
Immunotherapy: A 3D VASCULARIZED MICROFLUIDIC MODEL OF THE TUMOUR MICROENVIRONMENT FOR ASSAYING PSC DERIVED CAR-T CELL FUNCTION	12
Mesenchymal Stem/Stromal Cells: HYPERINFLAMMATION AND IMMUNE CELL DYSREGULATION IN C7 HYPOMORPHIC MOUSE MODEL OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA: IMMUNE AND INFLAMMATION MODULATION BY HUMAN	12
Mesenchymal Stem/Stromal Cells: DEVELOPMENT OF A HIGH-THROUGHPUT MICROGLIA MORPHOLOGICAL PROFILING ASSAY TO ASSESS MESENCHYMAL STROMAL CELL EXTRACELLULAR VESICLE POTENCY	12
iPSC: CLINICALLY COMPLIANT MATRIX FOR HUMAN ES AND IPSC CULTURE FOR PRECLINICAL AND CLINICAL THERAPY	12
Immunotherapy: HUMAN MYELOID-DERIVED SUPPRESSOR CELLS INDUCED WITH PROSTAGLANDIN E2 ARE MARKED WITH DOWNREGULATION OF PATHWAYS ASSOCIATED WITH CYTOKINE AND CHEMOKINE BINDING IN THE TRANSCRIPTOMIC PROF	12
Mesenchymal Stem/Stromal Cells: AMBIENT TEMPERATURE CULTURE OF MESENCHYMAL STROMAL CELLS IN HYALURONIC ACID HYDROGELS	12
Mesenchymal Stem/Stromal Cells: DIFFERENT SOURCES OF TISSUE-DERIVED MESENCHYMAL STROMAL CELLS SHOW INTRINSIC BIOENERGETIC PHENOTYPES	12
Process Development and Manufacturing: MAYO CLINIC CELLULAR THERAPY FELLOWSHIP: A MODEL FOR TRAINING THE LEADERS OF THE FUTURE	12
Hematopoietic Stem/Progenitor Cells and Engineering: NOVEL EVIDENCE THAT THE ABO BLOOD GROUP SHAPES ERYTHROPOIESIS AND RESULTS IN HIGHER HEMATOCRIT FOR BLOOD GROUP B CARRIERS	11
Regulatory Affairs, Quality Systems, Policy, and Ethics: LEARNING FROM ONE PATIENT’S JOURNEY TO CAR-T: A “ROLLER COASTER” OF HIGHS AND LOWS	11
Cytotoxicity of tumor antigen specific t cells- a tool for potency assessment in drug development	11
Process Development and Manufacturing: MANUFACTURE OF HIGHLY CONCENTRATED T CELLS DELIVERED INTO THE PANCREAS AND LIVER USING ENDOSCOPIC ULTRASONOGRAPHY: PRELIMINARY RESULTS OF AN IN VIVO FEASIBILITY	11
Mesenchymal Stem/Stromal Cells: SUBCUTANEOUS DELIVERY OF ALLOGENEIC INTERFERON-γ LICENSED BONE MARROW DERIVED MESENCHYMAL STROMAL CELL (IFN-γ MSC) FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI)	11
Immunotherapy: DEVELOPMENT OF A GMP-COMPATIBLE MANUFACTURING PROCESS FOR HIGHLY-EDITED, STEM-LIKE, METABOLICALLY FIT, VIRUS FREE CRISPR CAR T CELLS	11
Clinical scale facs-sorting and expansion of regulatory t cells (TREGS) for phase i clinical trial	11
Application of aber’s FUTURA® biomass probes to inform transfection and cell lysis in iCELLis® bioreactor-based AAV manufacturing	11
Designing robust contamination control in manufacturing - do we select isolators or biosafety cabinets?	11
Directly link T cell phenotype and function to genotype with the opto cell therapy development 1.0 workflow	11
Regulatory Affairs, Quality Systems, Policy, and Ethics: CO-CREATION OF A GUIDING FRAMEWORK TO ENGAGE PATIENTS IN PRECLINICAL LABORATORY RESEARCH: A DELIBERATIVE KNOWLEDGE SPACE APPROACH	11
Process Development and Manufacturing: OPTIMIZED REAGENTS FOR IMMUNOPOTENCY ASSAYS ON MESENCHYMAL STROMAL CELLS FOR CLINICAL USE	11
Construction of a sindbis virus replicase-based minicircle for transdifferentiation	11
Regulatory Affairs, Quality Systems, Policy, and Ethics: AN IN-HOUSE DEVELOPED EXTERNAL ASSURANCE PROGRAMME FOR ADVANCED THERAPIES, THE FIRST ACADEMIC PROGRAMME IN EUROPE	11
Process Development and Manufacturing: NOVEL SOFTWARE FOR ROBUST AND REPRODUCIBLE CLINICAL GRADE ENRICHMENT OF T REGULATORY CELLS EMPLOYING THE CLINIMACS PRODIGY	11
High-speed and high-precision fluorescence-based cell count and viability assays using the Cellaca™ MX high-throughput cell counter	11
Process Development and Manufacturing: IMPACT OF XENO-FREE AND SERUM FREE MEDIUM FORMULATIONS FOR CAR-T CELL MANUFACTURING	11
Process Development and Manufacturing: SCALABLE PRODUCTION OF INDUCED PLURIPOTENT STEM CELL-DERIVED CD8αβ+ CELLS IN STIRRED TANK REACTORS USING DLL4/ VCAM-1 COATED BEADS	11
Immunotherapy: OFF-THE-SHELF PARTIAL HLA MATCHING SARS-COV-2 ANTIGEN SPECIFIC T CELL THERAPY FOR SEVERE COVID-19 PATIENTS	10
Improved inter-instrument consistency and high precision for cho cell bioprocessing using the Cellaca™ MX high-throughput cell counter	10
Exosomes/EVs: MSC-EV PREPARATIONS WITH AND WITHOUT IMMUNOMODULATORY CAPABILITIES REVEAL COMPARABLE, DETERGENT RESISTANT ECTO-5’-NUCLEOTIDASE (CD73) ACTIVITIES	10
Immunotherapy: PHENOTYPIC INTER-DONOR VARIABILITY OF CORD BLOOD DERIVED NK CELLS CORRELATE WITH THEIR CYTOTOXIC POTENTIAL	10
Cytokine optimization of SARS-CoV-2 specific T-cells for therapeutic use	10
Immunotherapy: PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF IN-VITRO EXPANDED CORD BLOOD-DERIVED γδ T CELLS AS AN OFF-THE-SHELF ALTERNATIVE FOR CELLULAR IMMUNOTHERAPY	10
Immunotherapy: RAPID GENERATION OF CMV-SPECIFIC CD19 CAR T CELLS: PROTOCOL OPTIMIZATION AND CMV-CD19 CAR T CELL CHARACTERIZATION	10
Immunotherapy: B7H3-CAR NK CELLS AND DNR CO-TRANSDUCED NK SHOWS MAINTAIN THEIR POTENCY AGAINST TGF-B MEDIATED IMMUNE SUPPRESSION	10
ATAK™ receptors, harnessing innate immunity to program myeloid cells to kill cancer	10
Placenta-derived mesenchymal stem/stromal cells and secreted extracellular vesicles as novel treatments for multiple sclerosis	10
Process Development and Manufacturing: OVERCOMING BARRIERS IN VIRAL VECTOR MANUFACTURING: SMALL MOLECULE TARGETING OF ANTIVIRAL DEFENCES	10
Immunotherapy: IDENTIFICATION OF IMMUNOGENIC SIGNATURES IN HEPATOCELLULAR CARCINOMA GUIDES T CELLS AGAINST RELEVANT TARGETS FOR SUCCESSFUL IMMUNOTHERAPY	10
ALVEOLAR RECONSTRUCTION WITH THE USE OF ESTROMAL FRACTION OF BONE MARROW AUTOLOGOUS: A CASE REPORT	10
“Off-the-shelf” multi-virus-specific T-cell bank to treat ADV, BKV, JCV, CMV and EBV infections using a HLA- defined peptide platform	10
Immunotherapy: PHASE 1/2 MULTICENTER CLINICAL TRIAL OF TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION VIA INDUCED T CELLS WITH SUPPRESSING FUNCTIONS	9
Immunotherapy: INTRANASAL ADMINISTRATION OF MESENCHYMAL STEM CELLS FOR LOCAL DELIVERY OF ONCOLYTIC VIRUSES TO BRAIN TUMORS	9
AMPHIPATHIC CHITOSANS AS VECTORS FOR SIRNA DELIVERY	9
Immunotherapy: MECHANISMS REGULATING THE RESISTANCE OF NORMAL T-CELLS TO CD5 CAR-MEDIATED CYTOTOXICITY	9
Mesenchymal Stem/Stromal Cells: INVESTIGATING THE ROLE OF IL6 SIGNALING IN MESENCHYMAL STROMAL CELLS INTERACTIONS WITH MONOCYTE/MACROPHAGES IN OSTEOARTHRITIS	9
Safety intraparenchymal injection of allogenic placenta mesenchymal stem cells derived exosome in patients underwent decompressive craniectomy following malignant middle cerebral artery infarct, a ran	9
Fibrinogen-depleted human platelet lysate media supplementation produces superior t cell product ex-vivo	8
WFS1 Gene correction reverts abnormal er stress response in wolfram syndrome IPSCS	8
The contribution of human pancreatic mesenchymal cells to the generation of pancreatic ß cells from IPSC	8
Process Development and Manufacturing: CUSTOM CLOSED-SYSTEM PLATFORM FOR MANUFACTURE OF LENTIVIRAL-TRANSDUCED HEMATOPOIETIC STEM PROGENITOR CELLS FOR GENE THERAPY	8
Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: DEVELOPMENT OF AN EXPERIMENTAL MODEL THAT MIMICS TISSUE DAMAGE OF COMPOSITE INJURIES TO TEST A REPAIR CELL THERAPY	8
Embryonic, Organ and Other Tissue Specific Stem Cells: Late Breaking Abstract: EPITHELIAL BARRIER FUNCTION IS ENHANCED IN TRANSPLANTED HUMAN INTESTINAL ORGANOIDS WITH AN ENTERIC NERVOUS SYSTEM	8
Immuno-depletion and culture expansion drive divergence of the mesenchymal vs. skeletal stem cell transcriptomes	8
The effect of neurotrophic factors on the phenotype of mature midbrain dopaminergic neuron	8
Mesenchymal Stem/Stromal Cells: Late Breaking Abstract: A COMPARITIVE ANALYSIS OF THE MSC SECRETOME: HUMAN IPSC-DERIVED MSCS AND THEIR TISSUE-DERIVED COUNTERPARTS	8
Process Development and Manufacturing: GMP CLEAN ROOM SOLUTIONS AT FINNISH RED CROSS BLOOD SERVICE (FRCBS) FOR PRODUCTION OF ADVANCED CELL THERAPIES	8
Process Development and Manufacturing: DEVELOPMENT OF A DUAL CHAMBER DEVICE FOR THERAPEUTIC CELL TRANSPORT USING BIOMATERIAL AT AMBIENT TEMPERATURE	8
Neuromesodermal progenitors (NMPS) with primitive streak origin differentiate into functional mesenchymal stem cells (MSCS)	8
Process Development and Manufacturing: LENTIVIRAL VECTOR MANUFACTURING, A SUCCESSFUL AND REPRODUCIBLE CONTINUUM PROCESS FROM RESEARCH BATCHES TO CLINICAL APPLICATION	8
Hematopoietic Stem/Progenitor Cells and Engineering: HEMATOPOIETIC STEM/PROGENITOR CELLS (HPC-A) CRYOPRESERVATION PROCESS VALIDATION USING CRYOSTOR® CS10 FREEZE MEDIA	8
Extracellular vesicles in combination with a biological scaffold allow the regain of muscle function after volumetric muscle loss	8
Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: A SCAFFOLD-FREE GRAFT FOR LARGE CRITICAL SIZE BONE DEFECT: PRECLINICAL EVIDENCE TO CLINICAL PROOF OF CONCEPT	8
Regulatory Affairs, Quality Systems, Policy, and Ethics: THE EUROPEAN REGULATION ON HEALTH TECHNOLOGY ASSESSMENT: BALANCING EUROPEAN AND NATIONAL LEVELS	7
Automated aseptic sampling device for repeated aseptic sampling from bioreactor during cell manufacturing	7
First final release test of atmps prior to treatment -validation of a qpcr-based rapid sterility test	7
Effect of cryoprotectants on growth and detection of microorganisms using an automated culture system	7
The value of car t-cell therapies - the cases of yescarta & kymriah: results of a systematic review of the cost-effectiveness literature and evaluations of 2 hta bodies	7
Developing an adaptable manufacturing platform for the cgmp production of allogeneic t-cell therapies	7
Embryonic, Organ and Other Tissue Specific Stem Cells: EXPLORING THE ANTI-TUMOR EFFECTS OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELL SECRETOME ON PANCREATIC DUCTAL ADENOCARCINOMA CELLS IN CO	7
Tissue Engineering: WHITLOCKITE-MEDIATED HYPERTROPHIC CARTILAGE FORMATION TO FACILITATE OSSEOINTEGRATION OF ENGINEERED CARTILAGE GRAFT IN RABBIT OSTEOCHONDRAL DEFECT	7
Bioinspired knobby magnetic beads as an efficient platform for ex vivo activation and expansion of human immune cells	7
Hematopoietic Stem/Progenitor Cells and Engineering: HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC	7
Why qbd and digitisation are the foundation of the industrialisation of cell therapy	7
Process Development and Manufacturing: VALIDATION AND USE OF SHORT TANDEM REPEATS TO ESTABLISH UNIQUE MOLECULAR SIGNATURES IN CELL THERAPY PRODUCTS	7
Process Development and Manufacturing: IMPROVED DOWNSTREAM VIRUS PURIFICATION YIELD USING EXCIPIENT-GRADE RECOMBINANT ALBUMIN, EXBUMIN	7
Regulatory Affairs, Quality Systems, Policy, and Ethics: WHICH ACTORS TO INFLUENCE THE ADOPTION OF EU GUIDELINES FOR ADVANCED THERAPY MEDICINAL PRODUCTS?	7
Platelet-rich plasma derived from refrigerated whole blood as a source product for human platelet lysate production	7
Development of a scalable GMP-Ready manufacturing process for gene circuit engineered allogeneic CAR-NK cell therapy for cancer	7

Process Development and Manufacturing: MINIMIZING PARTICULATE CONTAMINATION IN SINGLE-USE SYSTEMS FOR BIOPHARMACEUTICAL AND PHARMACEUTICAL INDUSTRIES	7
Process Development and Manufacturing: A NEEDLE-BASED AUTOSAMPLER FOR BIOREACTOR CELL MEDIA COLLECTION	7
Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MAL	7
Regulatory Affairs, Quality Systems, Policy, and Ethics: DEVELOPING A MULTI-STAKEHOLDER INITIATIVE TO OVERCOME BARRIERS IN IMPLEMENTING FACT MANDATED QUALITY MANAGEMENT SYSTEM (QMS) IN AN INDIAN TRANS	7
Immunotherapy: EPHRIN RECEPTOR A3–TARGETED CAR T CELL IMMUNOTHERAPY FOR GLIOBLASTOMA	6
Immunotherapy: DEVELOPING OFF THE SHELF T CELL THERAPIES FOR HIGH-GRADE GLIOMAS	6
DESCRIPTION WITH FEW DETAILS IN THE PARAMETERS OF THE BIOMANUFACTURING OF BIOPRINTED CONSTRUCTS HARM BEGINNING RESEARCHERS	6
Gene Editing/Gene Therapies: DEVELOPING A NOVEL FEEDING STRATEGY FOR ENHANCED LENTIVIRAL VECTOR PRODUCTION	6
Immunotherapy: EVALUATION OF MEMORY T CELLS AS ADOPTIVE THERAPY IN CORONAVIRUS PNEUMONIA AND/OR LYMPHOPENIA: A PHASE II CLINICAL TRIAL (RELEASE NCT04578210)	6
Table of Contents	6
Mesenchymal Stem/Stromal Cells: CONSIDERATION OF COMPARTMENT EFFECT ON BIOMARKER ANALYSIS: LESSONS LEARNED FROM BRAINSTORM’S PHASE III CLINICAL TRIAL EVALUATING MSC-NTF CELL THERAPY IN ALS	6
Immunotherapy: HIGH EFFICIENCY MULTIPLEX CELL ENGINEERING OF ALLOGENEIC, NEXT GENERATION CHIMERIC ANTIGEN RECEPTOR T-CELLS USING A SINGLE BIMODAL GENE CONSTRUCT	6
Exosomes/EVs: LARGE-SCALE MANUFACTURING AND CHARACTERISATION OF EXTRACELLULAR VESICLES DERIVED FROM UMBILICAL CORD MESENCHYMAL STROMAL CELLS (MSC-EVS) IN A GMP COMPLIANT SYSTEM	6
Immunotherapy: COMPARISON OF CAR-T CELL-MEDIATED CYTOTOXICITY ASSAYS WITH SUSPENSION TUMOR CELLS USING HIGH-THROUGHPUT PLATE-BASED IMAGE CYTOMETRY METHOD	6
Process Development and Manufacturing: A NOVEL HIGHLY SCALABLE, MICROFLUIDIC APPROACH TO ELECTROPORATION	6
Immunotherapy: INFECTED HEPATOCYTE CLEARANCE AND SUSTAINED TUMOR REGRESSION BY FIRST-IN-CLASS HBSAG-SPECIFIC TCR-T (SCG101) THERAPY FOR HBV-RELATED HCC	6
Process Development and Manufacturing: CLOSED MICROFLUIDIC SYSTEM FOR MANUFACTURING DENDRITIC CELL THERAPIES	6
Exosomes/EVs: IMPACT OF THE PREPARATION OF CONDITIONED MEDIUM FROM MESENCHYMAL STROMAL CELLS ON ANTI-INFLAMMATORY PROPERTIES FOR FUTURE WOUND HEALING THERAPIES	6
THE EFFECT OF THE PRO-APOPTOTIC RHTRAIL PROTEIN IN THE PRESENCE OR ABSENCE OF THE COMBINATION WITH THE HSV-1 VIRUS IN HEAD AND NECK TUMOR LINES	6
Immunotherapy: APPLICATIONS OF IMMUNE PROFILING: QUANTITATIVE PHENOTYPIC ANALYSIS OF ALS PATIENTS RECEIVING MSC THERAPY	6
iPSC: A PHASE I CLINICAL TRIAL OF IPSC-DERIVED MSCS (CYP-001) IN STEROID-RESISTANT ACUTE GVHD: TWO YEAR FOLLOW-UP RESULTS	6
EFFECT OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS TRANSPLANTATION ON MITOCHONDRIAL DYNAMICS AND QUALITY IN A CHRONIC KIDNEY DISEASE MODEL	6
Process Development and Manufacturing: OPTIMISING PERFUSION PARAMETERS USING QUALITY BY DESIGN FOR THE INTENSIFIED PRODUCTION OF CAR T CELLS IN A SINGLE-USE AUTOMATED STIRRED-TANK BIOREACTOR	6
Mesenchymal Stem/Stromal Cells: MITOCHONDRIAL TRANSFER FUNCTIONALLY RESTORES THE HUMAN OSTEOARTHRITIS (OA) CHONDROCYTE, IS PROTECTIVE AGAINST OXIDATIVE STRESS AND IMPROVES OA IN AN ANIMAL MODEL OF DIS	6
Gene Editing/Gene Therapies: LENTIVIRAL VECTOR PLATFORM DEVELOPMENT FOR IMPROVED CHIMERIC ANTIGEN RECEPTOR T CELL APPLICATIONS	6
Immunotherapy: HIGH-ASPECT RATIO NANO-STRUCTURES FOR EFFICIENT, MINIMALLY PERTURBATIVE AND TRANSGENE-FREE IMMUNO-TRANSFECTION	6
Safety and feasibility of delayed infusion of stem cell products: a pilot study	6
THERAPEUTIC BENEFIT OF HUMAN WHARTON’S JELLY MESENCHYMAL STROMAL CELLS IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS	6
Immunotherapy: CLONAL ANALYSIS OF γδ IMMUNE RECONSTRUCTION POST αβHAPLO-HSCT	6
Regulatory Affairs, Quality Systems, Policy, and Ethics: LEARNING FROM EARLY PATIENT EXPERIENCES WITH CAR-T CELL THERAPY	6
Regulatory Affairs, Quality Systems, Policy, and Ethics: HOW INSTITUTIONAL BIOSAFETY COMMITTEES CONTRIBUTE TO SAFETY, CAPACITY AND REGULATORY APPROVALS IN CELL AND GENE THERAPY TRIALS	6
Mesenchymal Stem/Stromal Cells: DEFINING A MORE PREDICTABLE RECOVERY OF ADIPOSE DERIVED MESENCHYMAL STROMAL CELLS AFTER CRYOPRESERVATION	5
THE IMMUNOMODULATORY EFFECT OF UMBILICAL CORD MESENCHYMAL STEM CELLS PRODUCED UNDER XENO-FREE CONDITIONS	5
GENETIC INTEGRITY OF HUMAN ADIPOSE DERIVED MESENCHYMAL STROMAL CELLS FROM FACE AND ABDOMEN IN LONG-TERM CULTURE AND UVB RADIATION.	5
Process Development and Manufacturing: ENHANCEMENT OF BIOACTIVE AND CELL-LABELING PEPTIDES WITH DNA-TEMPLATED MULTIVALENCE	5
Gene Editing/Gene Therapies: A BREAKTHROUGH GLP AAV-ITR SANGER SEQUENCING SOLUTION FOR NEW DRUG DEVELOPMENT	5
Immunotherapy: Late Breaking Abstract: 3D BIODISTRIBUTION OF SUPT1 CELLS IN WHOLE MICE USING CRYOVIZ™ IMAGING	5
Mesenchymal Stem/Stromal Cells: REGULATION OF VASCULAR ENDOTHELIAL INTEGRITY IN HEMORRHAGIC SHOCK BY MESENCHYMAL STROMAL CELL EXTRACELLULAR VESICLES	5
CONSTRUCTION OF DEAD-CAS9 MACHINERY FOR ACTIVATION OF ENDOGENOUS NEUROPROTECTIVE TRANSCRIPTION FACTOR MAX IN VITRO	5
Mesenchymal Stem/Stromal Cells: TRANSFECTION OPTIMIZATION FOR GENERATING CLINICAL GRADE IL-10 mRNA ENGINEERED MSCS	5
Exosomes/EVs: LPS TREATMENT ENHANCES THE IMMUNOMODULATORY EFFECT OF MESENCHYMAL STROMAL CELLS-DERIVED EXTRACELLULAR VESICLES	5
Gene Editing/Gene Therapies: GDA-201: PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF CRYOPRESERVED NICOTINAMIDE-EXPANDED ALLOGENEIC NATURAL KILLER CELLS DEMONSTRATE AN ACTIVATED AND NON-EXHAUSTED PHENO	5
Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: MANUFACTURE OF IL-10+ REGULATORY B CELLS (BREGS) BY STIMULATION OF PERIPHERAL BLOOD B CELLS WITH ANTI–CD40 SINGLE-CHAIN VARIA	5
VALIDATION OF A CYTOTOXICITY ASSAY USING ADULT HUMAN MESENCHYMAL STEM CELLS AS AN ALTERNATIVE TO THE USE OF ANIMALS	5
iPSC: GMP-COMPLIANT HIPSC PRODUCTION AND QC-TESTING IN AN ACADEMIC SETTING	5
Mesenchymal Stem/Stromal Cells: IMPROVING CHONDROGENIC POTENCY OF MESENCHYMAL STROMAL CELLS BY EPIGENETIC STRATEGIES FOR CARTILAGE REPAIR	5
Immunotherapy: EXPANSION AND PROCESSING OF A CLINICALLY RELEVANT NUMBER OF NK CELLS	5
Modular biomimetic matrices enable highly defined culture of functional stem cells	5
Hematopoietic Stem/Progenitor Cells and Engineering: FROM HARMFUL TO USEFUL: EXPLOITING A LEUKEMIC TRANSCRIPTION FACTOR FOR LARGE-SCALE EX VIVO MANUFACTURE OF HUMAN MACROPHAGES	5
THE FREQUENCY OF PDPN+ CD146- HUMAN SKELETAL STEM CELLS AND ITS PROGENY VARIES IN ADULT BONES OF DIFFERENT ANATOMICAL LOCATIONS	5
Mesenchymal Stem/Stromal Cells: HEMOCOMPATIBILITY SAFETY TESTING OF INTRAVASCULAR CELLULAR THERAPIES: OPTIMIZING SAFETY, EFFICACY, AND CLINICAL DELIVERY OF REGENERATIVE AND IMMUNOMODULATORY MSC THERAP	5
Mesenchymal Stem/Stromal Cells: A COMBINATORIAL APPROACH TO ANALYZE EFFECTOR PATHWAYS OF CANINE ADIPOSE MESENCHYMAL STROMAL CELLS	5
Hematopoietic Stem/Progenitor Cells and Engineering: EVALUATION OF FACTORS THAT EFFECT MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM CELLS FROM PERIPHERAL BLOOD	5
Exosomes/EVs: Late Breaking Abstract: EFFECTS OF AMNIOTIC FLUID DERIVED EXTRACELLULAR VESICLE BIOLOGIC ON T CELL PROLIFERATION AND ACTIVATION	5
iPSC: A PHASE I/IIA TRIAL TO TEST SAFETY AND FEASIBILITY OF AN AUTOLOGOUS IPS CELL-DERIVED RETINAL PIGMENT EPITHELIUM PATCH IN AGE-RELATED MACULAR DEGENERATION PATIENTS	5
Immunomodulatory characterization of an umbilical cord-derived mesenchymal stromal cells (UC-MSCs)-based cell therapy	5
iPSC: TOWARDS MASS PRODUCTION OF HIPSC-DERIVED HEPATOCYTES WITH IMPROVED FUNCTIONALITY: A NATURE-INSPIRED BIOPROCESS	5
Nampt/visfatin: a new player to consider for the differentiation of mesenchymal stem cells into insulin producing cells	5
Gene Editing/Gene Therapies: LONG-TERM EFFECTS OF IN VIVO GENOME EDITING IN THE MOUSE RETINA USING CAMPYLOBACTER JEJUNI CAS9	5
Gene Editing/Gene Therapies: Late Breaking Abstract: RAPID QUANTIFICATION OF CAPSID CONTENT OF ADENO-ASSOCIATED VIRUSES (AAVS) BY CAPILLARY ELECTROPHORESIS-BASED WESTERN ANALYSIS	5
Mesenchymal Stem/Stromal Cells: OMEGA-SEC: PRIMING ADIPOSE-TISSUE MESENCHYMAL STEM CELLS SECRETOME WITH DOCOSAHEXAENOIC-ACID FOR REGENERATIVE MEDICINE APPLICATIONS IN THE CENTRAL NERVOUS SYSTEM	5
Exosomes/EVs: MSC-SEVS ALLEVIATE LOCAL AND SYSTEMIC INFLAMMATION TO PROMOTE JOINT REPAIR IN OSTEOARTHRITIS	5
Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium	5
iPSC: Late Breaking Abstract: A UNIVERSAL APPROACH TO TREAT CNS MANIFESTATIONS IN LYSOSOMAL STORAGE DISEASES USING IPSC-DERIVED MICROGLIA	5
Hematopoietic Stem/Progenitor Cells and Engineering: CHARACTERIZATION OF CRYOPRESERVED UMBILICAL CORD BLOOD BY GESTATIONAL AGE	5
Mesenchymal Stem/Stromal Cells: A PHASE 2 CLINICAL TRIAL OF REPEATED INTRATHECAL TREATMENT WITH AUTOLOGOUS ADIPOSE-DERIVED MSC IN AMYOTROPHIC LATERAL SCLEROSIS	5
Machine learning to predict mesenchymal stem cell efficacy for cartilage repair	5
Mesenchymal Stem/Stromal Cells: SPATIAL TRANSCRIPTOMICS IDENTIFIES PRO-ANGIOGENIC PERIVASCULAR STEM CELLS IN ADIPOSE TISSUE	4
Immunotherapy: 1ST-IN-HUMAN CAR T TARGETS THE GROWTH FACTOR RECEPTOR FORM OF MUC1	4
Welcome to ISCT 2023	4
Mesenchymal Stem/Stromal Cells: CELLULAR AGING SECRETES: A COMPARISON OF BONE MARROW DERIVED AND INDUCED MESENCHYMAL STEM CELLS AND THEIR SECRETOME OVER LONG TERM CULTURE	4
Immunotherapy: LONG-TERM CRYOPRESERVED PERIPHERAL BLOOD MONONUCLEATED CELLS (PBMCS) DERIVED NATURAL KILLER CELLS RETAIN THEIR CELL FREQUENCY AND PROLIFERATION ABILITY	4
GENERATION AND OPTIMIZATION OF ANTI-CD19 CAR-T CELL FOR LEUKEMIA IMMUNOTHERAPY	4
Immunotherapy: FEEDER-CELL-FREE NATURAL KILLER CELL EXPANSION USING NK CLOUDZ AND THE G-REX CULTURE SYSTEM	4
GMP compliant protocol for the isolation and expansion of mesenchymal stem cells derived from human endometrium	4
Mesenchymal Stem/Stromal Cells: CAN PRIMING APPROACHES IMPROVE THE IMMUNOREGULATORY CAPABILITY OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS TO TREAT PANCREATIC CANCER?	4
Exosomes/EVs: CD10-BOUND HUMAN INFRAPATELLAR FAT PAD MESENCHYMAL STEM CELL-DERIVED EXOSOMES ATTENUATE PRO-INFLAMMATORY SIGNALING: AN ALTERNATIVE FOR SYNOVITIS AND FAT PAD FIBROSIS TREATMENT	4
Exosomes/EVs: A PRECISE STIMULATION OF STEM CELLS IN BIOREACTORS TO INDUCE MASSIVE PRODUCTION OF EXTRACELLULAR VESICLES	4
Immunotherapy: RAPID EXPANSION PROTOCOL OPTIMIZATION FOR TUMOR INFILTRATING LYMPHOCYTES	4
Immunotherapy: TARGETING EWING SARCOMA (ES), OSTEOSARCOMA (OS) AND NEUROBLASTOMA (NB) WITH ANTI-MCAM CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED NATURAL KILLER (NK) CELLS	4
Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: DEVELOPING AND CHARACTERIZING AN OSTEOCHONDRAL-SYNOVIUM MODEL FOR EVALUATING PSORIATIC ARTHRITIS THERAPIES	4
Gene Editing/Gene Therapies: A NOVEL METHOD FOR ASSESSING FULL-LENGTH SEQUENCE INTEGRITY OF RNA THERAPEUTICS	4
Hematopoietic Stem/Progenitor Cells and Engineering: A NEW METHOD FOR THE AUTOMATED ENUMERATION AND ANALYSIS OF CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS BY FLOW CYTOMETRY	4
Exosomes/EVs: DEVELOPMENT OF A TAILORED CELL-FREE THERAPEUTIC APPROACH BASED ON MSC-EXOSOMES FOR ACUTE HEPATIC FAILURE	4
Use of platelet lysate as an alternative for fbs in generating clinical grade mesenchymal stem cells – a pilot study	4
Exosomes/EVs: SECRETOME PROFILE FROM INDUCED HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS UNVEILS BIOLOGICAL PROCESSES RELEVANT TO WOUND HEALING	4
Immunotherapy: Late Breaking Abstract: OPTICAL METABOLIC IMAGING FOR LABEL-FREE FUNCTIONAL EVALUATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS	4
Abstract Program at a Glance	4
Exosomes/EVs: CONJUGATION OF A HIGH-AFFINITY INTEGRIN LIGAND TO THE SURFACE OF STEM CELL-DERIVED EXTRACELLULAR VESICLES FOR TARGETED DELIVERY	4
Gene Editing/Gene Therapies: SCALABLE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS IN DIFFERENT SINGLE- USE BIOREACTOR PLATFORMS	4
iPSC: DEVELOPMENT OF AUTOMATED CELL AND COLONY MANAGEMENT PROTOCOLS FOR GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELLS	4
GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELL LINES DERIVED FROM TWO BRAZILIAN PATIENTS WITH HUTCHINSON-GILFORD PROGERIA SYNDROME CARRYING C.1824 C>T MUTATION	4
Gene Editing/Gene Therapies: LEVERAGING SINGLE-CELL DNA SEQUENCING FOR IN-DEPTH CHARACTERIZATION OF CELL AND GENE THERAPIES	4
Characterization of osteoarthritis-derived cartilage and infrapatellar fat pad mesenchymal stromal cells expanded in human platelet lysate	4
Results of the cellular immuno-therapy for covid-19 related acute respiratory distress syndrome (circa-phase i trial	4